See more : ASG Plastic Factory Co. (9607.SR) Income Statement Analysis – Financial Results
Complete financial analysis of IGM Biosciences, Inc. (IGMS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IGM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- 3DShopping.com (THDS) Income Statement Analysis – Financial Results
- Pranda Jewelry Public Company Limited (PDJ.BK) Income Statement Analysis – Financial Results
- Nordic Halibut AS (NOHAL.OL) Income Statement Analysis – Financial Results
- Azelio AB (publ) (AZLOF) Income Statement Analysis – Financial Results
- Jiangsu Hongtu High Technology Co., Ltd. (600122.SS) Income Statement Analysis – Financial Results
IGM Biosciences, Inc. (IGMS)
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.13M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| Gross Profit | -6.15M | -9.53M | -7.72M | -3.58M | -2.33M | -278.00K | -161.00K |
| Gross Profit Ratio | -288.59% | -891.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 215.52M | 179.29M | 127.03M | 65.03M | 35.26M | 18.96M | 8.64M |
| General & Administrative | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Other Expenses | 0.00 | -181.00K | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Operating Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Cost & Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Interest Income | 17.74M | 7.04M | 159.00K | 1.93M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| EBITDA | -253.36M | -221.88M | -157.44M | -77.78M | -40.80M | -22.51M | -10.99M |
| EBITDA Ratio | -11,894.74% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -263.46M | -227.96M | -165.32M | -83.28M | -44.50M | -22.79M | -11.15M |
| Operating Income Ratio | -12,369.06% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.72M | 6.85M | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Income Before Tax | -245.74M | -221.10M | -165.16M | -81.36M | -43.13M | -22.71M | -11.05M |
| Income Before Tax Ratio | -11,537.00% | -20,683.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 678.00K | -6.85M | -4.48M | -1.03M | -597.00K | 80.00K | 0.00 |
| Net Income | -246.42M | -214.25M | -160.68M | -80.33M | -42.54M | -22.71M | -11.05M |
| Net Income Ratio | -11,568.83% | -20,041.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| EPS Diluted | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| Weighted Avg Shares Out | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
| Weighted Avg Shares Out (Dil) | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday
Nomination Committee of Medivir appointed
Change in Medivir's Board of Directors
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.
Medivir to present at the Pareto Securities Healthcare Conference
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima
Source: https://incomestatements.info
Category: Stock Reports